The Man Who Taught Big Pharma to Date Startups Is Leaving

The common thread: Plump didn't just want to buy late-stage drugs at a premium. He wanted to shape the startup ecosystem early, sometimes before these companies even had a lead product. It's the difference between buying a house and buying the land, then helping design the blueprints.

Three for Three

Of course, a fancy strategy means nothing if the drugs don't work. And for a while, skeptics had a point; Plump's transformation took years to bear fruit, and some bets (including certain cell therapy efforts) got cut along the way.

But 2025 turned into a vindication lap. Takeda posted positive Phase 3 results for oveporexton, which made a particularly loud splash: in a head-to-head psoriasis trial for zasocitinib, more than 35% of patients hit a complete skin clearance score at week 16, outperforming the comparator drug deucravacitinib.

Takeda now says it has three "transformative medicines" poised for launch in the coming months, along with a robust late-stage pipeline that includes 6 to 8 clinical programs. For a company that needed a full R&D overhaul just a decade ago, that's a remarkable turnaround.

Why Big Pharma Was Taking Notes

Plump's playbook landed at exactly the right moment. The entire pharmaceutical industry was grappling with the same uncomfortable truth: internal R&D productivity was declining, and the best science was increasingly coming from scrappy biotech startups running on venture capital and caffeine.

The industry response has been a massive shift toward what analysts call "external innovation." Eli Lilly built its ExploR&D/Catalyze360 platform with more than 90 collaborations. Deal structures evolved from simple royalty arrangements into 50/50 co-development partnerships with shared risk and reward. Big pharma, in other words, stopped trying to be the sole inventor and started building repeatable engines for finding and nurturing outside talent.

Plump didn't invent this trend single-handedly. But Takeda became one of its clearest success stories, and the model he built (narrow your focus, diversify your partners, engage early) is now essentially the playbook every large pharma R&D chief has pinned to their wall.

The Succession Question

Takeda hasn't named a replacement yet, and that's worth watching. Plump's strategy isn't just a set of deals on a spreadsheet; it's a culture. He transformed a company that was used to doing things internally and convinced it to trust external partners with its future. Maintaining that cultural shift requires a successor who genuinely believes in the model, not someone who pays it lip service while quietly rebuilding the fortress.

Plump himself came from stints at Merck (where he led worldwide cardiovascular research) and Sanofi (as Senior Vice President of Research & Translational Medicine). He joined Takeda as Chief Medical and Scientific Officer before becoming R&D President in 2018. That progression from scientific leader to strategic architect is exactly the kind of experience Takeda will need to find in its next hire.

The Bigger Picture

Retirements in pharma usually generate a polite press release and a quick LinkedIn scroll. This one matters more than most. Plump's legacy isn't just the drugs in Takeda's pipeline or the partnerships on its books. It's the proof of concept that a pharmaceutical company founded in 1781 can completely reinvent how it discovers medicines.

The question now is whether Takeda can keep it going without the architect in the room. History suggests that transformations driven by a single visionary leader are fragile things. The next R&D president won't just inherit a pipeline. They'll inherit a philosophy, and the pressure to prove it wasn't a one-man show.

BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer

BridgeBio Oncology pulled its lead KRAS drug out of the lucrative first-line lung cancer race, shrinking from a 200,000-patient opportunity to roughly 50,000. The stock dropped 24% in a single session, and the competitive fallout is just getting started.